DK1539166T3 - Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme - Google Patents

Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme

Info

Publication number: DK1539166T3
Authority: DK; Denmark
Prior art keywords: quinidine; pharmaceutical compositions; neurological disorders; treatment; compositions containing
Prior art date: 2002-07-17

Application number

DK03764769T

Other languages

English (en)

Inventor

Gerald Yakatan

James Berg

Richard A Smith

Laura E Pope

Original Assignee

Avanir Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-17

Filing date

2003-07-17

Publication date

2008-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30116047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1539166(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-17 Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals

2008-10-20 Application granted granted Critical

2008-10-20 Publication of DK1539166T3 publication Critical patent/DK1539166T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)

DK03764769T 2002-07-17 2003-07-17 Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme DK1539166T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39666102P	2002-07-17	2002-07-17
PCT/US2003/022303 WO2004006930A1 (en)	2002-07-17	2003-07-17	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Publications (1)

Publication Number	Publication Date
DK1539166T3 true DK1539166T3 (da)	2008-10-20

Family

ID=30116047

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03764769T DK1539166T3 (da)	2002-07-17	2003-07-17	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK08154443.9T DK1980252T3 (da)	2002-07-17	2003-07-17	Farmaceutiske sammensætninger omfattende dextromethorphan og quinidin til behandlingen af neurologiske forstyrrelser

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08154443.9T DK1980252T3 (da)	2002-07-17	2003-07-17	Farmaceutiske sammensætninger omfattende dextromethorphan og quinidin til behandlingen af neurologiske forstyrrelser

Country Status (24)

Country	Link
US (12)	US7659282B2 (da)
EP (6)	EP1980252B1 (da)
JP (12)	JP5082032B2 (da)
KR (7)	KR101622446B1 (da)
AT (1)	ATE399553T1 (da)
AU (3)	AU2003251971B9 (da)
BE (1)	BE2013C064I2 (da)
CA (1)	CA2492081C (da)
CY (2)	CY1110405T1 (da)
DE (1)	DE60321929D1 (da)
DK (2)	DK1539166T3 (da)
ES (2)	ES2553654T3 (da)
FR (1)	FR13C0062I2 (da)
HK (2)	HK1076052A1 (da)
HU (2)	HUE028100T2 (da)
IL (7)	IL166166A0 (da)
LU (1)	LU92323I2 (da)
NO (2)	NO330626B1 (da)
PL (2)	PL398445A1 (da)
PT (2)	PT1980252E (da)
RU (1)	RU2341265C2 (da)
SI (2)	SI1539166T1 (da)
TW (1)	TWI326214B (da)
WO (1)	WO2004006930A1 (da)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI326214B (en) *	2002-07-17	2010-06-21	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7754767B2 (en) *	2002-11-06	2010-07-13	Trinity Laboratories, Inc.	Method for treatment of premature ejaculation in humans
CA2561993A1 (en) *	2004-03-30	2006-04-13	Painceptor Pharma Corporation	Compositions and methods for modulating gated ion channels
US20070191411A1 (en) *	2004-10-07	2007-08-16	Smith Richard A	Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US20060205822A1 (en) *	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2641392A1 (en) *	2006-02-03	2007-08-16	Avanir Pharmaceuticals	Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
US20160143901A1 (en) *	2006-02-03	2016-05-26	Avanir Pharmaceuticals, Inc.	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
EP2345653B1 (en) *	2007-05-01	2012-12-26	Concert Pharmaceuticals Inc.	Morphinan compounds
HUE063526T2 (hu)	2007-05-01	2024-01-28	Concert Pharmaceuticals Ind Inc	Morfinvegyületek
MX341177B (es)	2007-05-01	2016-08-10	Concert Pharmaceuticals Inc	Compuestos de morfina.
WO2009006194A1 (en) *	2007-06-28	2009-01-08	Avanir Pharmaceuticals	Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2010033801A1 (en)	2008-09-19	2010-03-25	Concert Pharmaceuticals Inc.	Morphinan compounds
US20120122848A1 (en) *	2009-07-29	2012-05-17	Green Cross Corporation	(+)-3-hydroxymorphinan derivatives as neuroprotectants
CA2712848A1 (en) *	2009-08-28	2011-02-28	Avanir Pharmaceuticals, Inc.	A method of reducing cns and gastrointestinal side affects associated with long-term, dextromethorphan/low-dose quinidine combination therapy
KR20130061148A (ko) *	2010-05-03	2013-06-10	티에스에이치 바이오팜 코포레이션 리미티드	고혈압 치료용 약학 조성물 및 방법
EP2686312B1 (en) *	2011-03-14	2016-08-31	Boehringer Ingelheim International GmbH	N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
US8569328B1 (en) *	2011-05-24	2013-10-29	Antecip Bioventures Ii Llc	Compositions and methods comprising tilidine or related compounds and dextromethorphan
EP2718288B1 (en)	2011-06-09	2015-03-11	Boehringer Ingelheim International GmbH	Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
US20130274282A1 (en) *	2012-04-16	2013-10-17	Herriot Tabuteau	Compositions and methods comprising celecoxib or related compounds and dextromethorphan
US10835495B2 (en)	2012-11-14	2020-11-17	W. R. Grace & Co.-Conn.	Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
CN103073496B (zh) *	2013-02-18	2015-08-26	苏州立新制药有限公司	右美沙芬的制备方法
WO2014138669A1 (en)	2013-03-07	2014-09-12	Mindlab LLC	Pain medicine combination and uses thereof
US11123344B2 (en)	2013-11-05	2021-09-21	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
US9408815B2 (en)	2013-11-05	2016-08-09	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11147808B2 (en)	2013-11-05	2021-10-19	Antecip Bioventures Ii Llc	Method of decreasing the fluctuation index of dextromethorphan
US10688066B2 (en)	2018-03-20	2020-06-23	Antecip Bioventures Ii Llc	Bupropion and dextromethorphan for treating nicotine addiction
US10786469B2 (en)	2013-11-05	2020-09-29	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11357744B2 (en)	2013-11-05	2022-06-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11285118B2 (en)	2013-11-05	2022-03-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11207281B2 (en)	2013-11-05	2021-12-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11129826B2 (en)	2013-11-05	2021-09-28	Axsome Therapeutics, Inc.	Bupropion as a modulator of drug activity
US11191739B2 (en)	2013-11-05	2021-12-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11426401B2 (en) *	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11213521B2 (en)	2013-11-05	2022-01-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9867819B2 (en) *	2013-11-05	2018-01-16	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10966941B2 (en)	2013-11-05	2021-04-06	Antecip Bioventures Ii Llp	Bupropion as a modulator of drug activity
US10898453B2 (en)	2013-11-05	2021-01-26	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10772850B2 (en)	2013-11-05	2020-09-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10894047B2 (en)	2013-11-05	2021-01-19	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9474731B1 (en)	2013-11-05	2016-10-25	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20220233470A1 (en)	2013-11-05	2022-07-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11541021B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11311534B2 (en)	2013-11-05	2022-04-26	Antecip Bio Ventures Ii Llc	Bupropion as a modulator of drug activity
EP3981404A1 (en) *	2013-11-05	2022-04-13	Antecip Bioventures II LLC	Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9198905B2 (en)	2013-11-05	2015-12-01	Antecip Bioventures Ii Llc	Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US11571399B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10864209B2 (en)	2013-11-05	2020-12-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11065248B2 (en)	2013-11-05	2021-07-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10105361B2 (en)	2013-11-05	2018-10-23	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11571417B2 (en)	2013-11-05	2023-02-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11364233B2 (en)	2013-11-05	2022-06-21	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11576877B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as modulator of drug activity
US10874665B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10933034B2 (en)	2013-11-05	2021-03-02	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11497721B2 (en)	2013-11-05	2022-11-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10940124B2 (en)	2019-01-07	2021-03-09	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11141416B2 (en)	2013-11-05	2021-10-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10945973B2 (en)	2013-11-05	2021-03-16	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11617728B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11478468B2 (en)	2013-11-05	2022-10-25	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11596627B2 (en)	2013-11-05	2023-03-07	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10813924B2 (en)	2018-03-20	2020-10-27	Antecip Bioventures Ii Llc	Bupropion and dextromethorphan for treating nicotine addiction
US11524007B2 (en)	2013-11-05	2022-12-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9457025B2 (en)	2013-11-05	2016-10-04	Antecip Bioventures Ii Llc	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10874664B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20200261431A1 (en)	2019-01-07	2020-08-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9707191B2 (en)	2013-11-05	2017-07-18	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11426370B2 (en)	2013-11-05	2022-08-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11517543B2 (en)	2013-11-05	2022-12-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10799497B2 (en)	2013-11-05	2020-10-13	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US11617747B2 (en)	2013-11-05	2023-04-04	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11541048B2 (en)	2013-11-05	2023-01-03	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11382874B2 (en)	2013-11-05	2022-07-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11510918B2 (en)	2013-11-05	2022-11-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10881657B2 (en)	2013-11-05	2021-01-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11291665B2 (en)	2013-11-05	2022-04-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11433067B2 (en)	2013-11-05	2022-09-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11419867B2 (en)	2013-11-05	2022-08-23	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20200338022A1 (en)	2019-01-07	2020-10-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10894046B2 (en)	2013-11-05	2021-01-19	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10966974B2 (en)	2013-11-05	2021-04-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10874663B2 (en)	2013-11-05	2020-12-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9968568B2 (en)	2013-11-05	2018-05-15	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10512643B2 (en) *	2013-11-05	2019-12-24	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273134B2 (en)	2013-11-05	2022-03-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11590124B2 (en)	2013-11-05	2023-02-28	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9763932B2 (en)	2013-11-05	2017-09-19	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11344544B2 (en)	2013-11-05	2022-05-31	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298352B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11058648B2 (en)	2013-11-05	2021-07-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11285146B2 (en)	2013-11-05	2022-03-29	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10080727B2 (en)	2013-11-05	2018-09-25	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11291638B2 (en)	2013-11-05	2022-04-05	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10105327B2 (en)	2013-11-05	2018-10-23	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US11534414B2 (en)	2013-11-05	2022-12-27	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9861595B2 (en)	2013-11-05	2018-01-09	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11576909B2 (en)	2013-11-05	2023-02-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11234946B2 (en)	2013-11-05	2022-02-01	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11096937B2 (en)	2013-11-05	2021-08-24	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11123343B2 (en)	2013-11-05	2021-09-21	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253492B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10966942B2 (en)	2019-01-07	2021-04-06	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11969421B2 (en)	2013-11-05	2024-04-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9457023B1 (en)	2013-11-05	2016-10-04	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11007189B2 (en)	2013-11-05	2021-05-18	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US10980800B2 (en)	2013-11-05	2021-04-20	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11439636B1 (en) *	2013-11-05	2022-09-13	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11273133B2 (en)	2013-11-05	2022-03-15	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11197839B2 (en)	2013-11-05	2021-12-14	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11020389B2 (en)	2013-11-05	2021-06-01	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US9402843B2 (en) *	2013-11-05	2016-08-02	Antecip Bioventures Ii Llc	Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9700528B2 (en)	2013-11-05	2017-07-11	Antecip Bioventures Ii Llc	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20160361305A1 (en)	2013-11-05	2016-12-15	Antecip Bioventures Ii Llc	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11229640B2 (en)	2013-11-05	2022-01-25	Antecip Bioventures Ii Llc	Combination of dextromethorphan and bupropion for treating depression
US12109178B2 (en)	2013-11-05	2024-10-08	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US20160324807A1 (en)	2013-11-05	2016-11-10	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11253491B2 (en)	2013-11-05	2022-02-22	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11298351B2 (en)	2013-11-05	2022-04-12	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11185515B2 (en)	2013-11-05	2021-11-30	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
US11090300B2 (en)	2013-11-05	2021-08-17	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
RU2017112747A (ru) *	2014-09-14	2018-10-15	Аванир Фармасьютикалз, Инк.	Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
US20160184290A1 (en) *	2014-12-31	2016-06-30	Paul J. Markovitz	Method of treating schizophrenia
WO2017020016A1 (en) *	2015-07-30	2017-02-02	Concert Pharmaceuticals, Inc.	Morphinan compounds for treating agitation
WO2017117347A1 (en) *	2015-12-30	2017-07-06	Markovitz M D Paul	Method of treating schizophrenia
EP3478664B1 (en)	2016-07-04	2020-12-02	Avanir Pharmaceuticals, Inc.	Methods for the synthesis of deuterated dextromethorphan
WO2018031216A1 (en) *	2016-08-12	2018-02-15	Steven Rothman	Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
AU2017315947B2 (en) *	2016-08-26	2022-12-01	Exciva GmbH	Compositions and methods thereof
US20190358208A1 (en)	2016-09-13	2019-11-28	Mindlab LLC	Medicine combinations and treatment of restless leg syndrome
US11478467B2 (en)	2017-05-04	2022-10-25	Sreenivasarao Vepachedu	Targeted drug rescue with novel compositions, combinations, and methods thereof
KR20200062078A (ko) *	2017-05-04	2020-06-03	익스시바 게엠베하	신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
TWI795446B (zh)	2017-10-04	2023-03-11	美商神經治療股份有限公司	右旋美索芬(dextromethorphan)經皮輸送裝置
US10925842B2 (en)	2019-01-07	2021-02-23	Antecip Bioventures Ii Llc	Bupropion as a modulator of drug activity
CN114469882B (zh) *	2022-04-06	2023-10-20	北京剂泰医药科技有限公司	一种右美沙芬奎尼丁口崩片及其应用
CN114569742B (zh) *	2022-05-09	2022-07-19	北京剂泰医药科技有限公司	一种组合物及其制备方法和应用
US11717518B1 (en)	2022-06-30	2023-08-08	Antecip Bioventures Ii Llc	Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en)	2022-07-07	2023-08-22	Antecip Bioventures Ii Llc	Treatment of depression in certain patient populations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4316888A (en) *	1980-04-15	1982-02-23	Nelson Research & Development Co.	Method and composition of reducing pain
US4806543A (en)	1986-11-25	1989-02-21	Board Of Trustees Of The Leland Stanford Junior University	Method and compositions for reducing neurotoxic injury
US5034400A (en)	1989-10-20	1991-07-23	Olney John W	Method for preventing neurotoxic side effects of NMDA antagonists
JP2893866B2 (ja) *	1990-05-25	1999-05-24	日本油脂株式会社	抗不整脈薬
US5350756A (en)	1991-06-17	1994-09-27	Smith Richard A	Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5206248A (en)	1992-03-27	1993-04-27	Smith Richard A	Method for reducing emotional lability
US5366980A (en) *	1991-06-17	1994-11-22	Smith Richard A	Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5166207A (en)	1991-06-17	1992-11-24	Neurotherapeutics, Inc.	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5321012A (en) *	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) *	1993-03-05	1994-10-04	Virginia Commonwealth University Medical College Of Virginia	Method for the treatment of chronic pain
CA2115792C (en) *	1993-03-05	2005-11-01	David J. Mayer	Method for the treatment of pain
ES2268686T3 (es) *	1994-09-22	2007-03-16	Richard Alan Smith	Combinacion de dextrometorfano con quinidina o sulfato de quinina para tratar diversos trastornos de dificil cura.
EP0784621B1 (en) *	1995-08-03	2001-10-31	Dade Behring Inc.	Quinidine conjugates and their use in immunoassays
AU6328099A (en)	1998-09-21	2000-04-10	Transgene S.A.	Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
WO2000059486A2 (en) *	1999-04-07	2000-10-12	Pfizer Products Inc.	Use of cyp2d6 inhibitors in combination therapies
US6207674B1 (en) *	1999-12-22	2001-03-27	Richard A. Smith	Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6924273B2 (en)	2000-10-03	2005-08-02	Scott W. Pierce	Chondroprotective/restorative compositions and methods of use thereof
US20040087479A1 (en)	2001-04-30	2004-05-06	Sosnowski Robert E.	Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
TWI326214B (en) *	2002-07-17	2010-06-21	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA2641392A1 (en) *	2006-02-03	2007-08-16	Avanir Pharmaceuticals	Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
KR101590378B1 (ko) *	2009-09-07	2016-02-02	에스케이텔레콤 주식회사	근거리 영역 내의 방송통신 융합 구간에 대한 신호 간섭 최소화 시스템 및 방법, 그리고 이에 적용되는 장치

2003
- 2003-07-15 TW TW092119228A patent/TWI326214B/zh not_active IP Right Cessation
- 2003-07-17 KR KR1020137005412A patent/KR101622446B1/ko active IP Right Grant
- 2003-07-17 JP JP2004521935A patent/JP5082032B2/ja not_active Expired - Lifetime
- 2003-07-17 EP EP08154443.9A patent/EP1980252B1/en not_active Expired - Lifetime
- 2003-07-17 AU AU2003251971A patent/AU2003251971B9/en not_active Expired
- 2003-07-17 KR KR1020137005416A patent/KR101588095B1/ko active IP Right Grant
- 2003-07-17 RU RU2005104418/14A patent/RU2341265C2/ru active
- 2003-07-17 KR KR1020197037633A patent/KR20190143466A/ko not_active Application Discontinuation
- 2003-07-17 CA CA2492081A patent/CA2492081C/en not_active Expired - Lifetime
- 2003-07-17 PL PL398445A patent/PL398445A1/pl unknown
- 2003-07-17 KR KR1020127011436A patent/KR20120089706A/ko not_active Application Discontinuation
- 2003-07-17 EP EP17170411.7A patent/EP3281630A1/en not_active Withdrawn
- 2003-07-17 WO PCT/US2003/022303 patent/WO2004006930A1/en active Application Filing
- 2003-07-17 KR KR1020167011631A patent/KR20160055963A/ko not_active Application Discontinuation
- 2003-07-17 AT AT03764769T patent/ATE399553T1/de active
- 2003-07-17 EP EP18188054.3A patent/EP3459547A1/en not_active Withdrawn
- 2003-07-17 SI SI200331353T patent/SI1539166T1/sl unknown
- 2003-07-17 DK DK03764769T patent/DK1539166T3/da active
- 2003-07-17 ES ES08154443.9T patent/ES2553654T3/es not_active Expired - Lifetime
- 2003-07-17 EP EP20201438.7A patent/EP3824889A1/en not_active Withdrawn
- 2003-07-17 PT PT81544439T patent/PT1980252E/pt unknown
- 2003-07-17 DK DK08154443.9T patent/DK1980252T3/da active
- 2003-07-17 ES ES03764769T patent/ES2309351T3/es not_active Expired - Lifetime
- 2003-07-17 KR KR1020117000825A patent/KR20110010669A/ko not_active Application Discontinuation
- 2003-07-17 HU HUE08154443A patent/HUE028100T2/en unknown
- 2003-07-17 SI SI200332454T patent/SI1980252T1/sl unknown
- 2003-07-17 DE DE60321929T patent/DE60321929D1/de not_active Expired - Lifetime
- 2003-07-17 EP EP10185871A patent/EP2322179A1/en not_active Withdrawn
- 2003-07-17 KR KR1020057001114A patent/KR20050043893A/ko not_active Application Discontinuation
- 2003-07-17 PT PT03764769T patent/PT1539166E/pt unknown
- 2003-07-17 EP EP03764769A patent/EP1539166B1/en not_active Expired - Lifetime
- 2003-07-17 PL PL374026A patent/PL213552B1/pl unknown
2005
- 2005-01-05 IL IL16616605A patent/IL166166A0/xx unknown
- 2005-01-12 US US11/035,213 patent/US7659282B2/en active Active
- 2005-02-15 NO NO20050807A patent/NO330626B1/no not_active IP Right Cessation
- 2005-11-21 HK HK05110514A patent/HK1076052A1/xx not_active IP Right Cessation
2008
- 2008-04-22 AU AU2008201775A patent/AU2008201775B2/en not_active Expired
- 2008-09-30 CY CY20081101086T patent/CY1110405T1/el unknown
- 2008-11-25 US US12/323,214 patent/US20090082384A1/en not_active Abandoned
2009
- 2009-04-15 HK HK09103462.4A patent/HK1123741A1/xx not_active IP Right Cessation
2010
- 2010-02-03 US US12/699,408 patent/US20100137352A1/en not_active Abandoned
- 2010-08-13 AU AU2010212348A patent/AU2010212348B2/en not_active Expired
2011
- 2011-03-06 IL IL211593A patent/IL211593A0/en unknown
- 2011-07-15 JP JP2011157054A patent/JP2011225601A/ja active Pending
2012
- 2012-02-07 JP JP2012024387A patent/JP2012116858A/ja active Pending
- 2012-03-08 US US13/415,067 patent/US8227484B2/en not_active Expired - Fee Related
- 2012-11-16 US US13/679,256 patent/US20130072517A1/en not_active Abandoned
2013
- 2013-03-13 IL IL225191A patent/IL225191A/en active IP Right Grant
- 2013-03-13 IL IL225190A patent/IL225190A/en active IP Right Grant
- 2013-03-13 IL IL225192A patent/IL225192A/en active IP Right Grant
- 2013-10-21 US US14/059,058 patent/US20140045880A1/en not_active Abandoned
- 2013-11-08 CY CY2013041C patent/CY2013041I1/el unknown
- 2013-11-14 HU HUS1300069C patent/HUS1300069I1/hu unknown
- 2013-11-20 BE BE2013C064C patent/BE2013C064I2/fr unknown
- 2013-11-21 NO NO2013017C patent/NO2013017I2/no not_active IP Right Cessation
- 2013-11-22 FR FR13C0062C patent/FR13C0062I2/fr active Active
- 2013-12-04 LU LU92323C patent/LU92323I2/xx unknown
- 2013-12-27 JP JP2013272584A patent/JP2014058575A/ja active Pending
2014
- 2014-02-26 JP JP2014035209A patent/JP2014129384A/ja active Pending
- 2014-06-06 US US14/298,571 patent/US20140288114A1/en not_active Abandoned
2015
- 2015-04-07 US US14/680,275 patent/US20150209347A1/en not_active Abandoned
- 2015-09-16 JP JP2015182769A patent/JP6074000B2/ja not_active Expired - Lifetime
2016
- 2016-03-16 JP JP2016051838A patent/JP6097859B2/ja not_active Expired - Lifetime
- 2016-04-06 US US15/092,316 patent/US20160287576A1/en not_active Abandoned
- 2016-11-21 JP JP2016225766A patent/JP6332651B2/ja not_active Expired - Lifetime
2017
- 2017-02-17 JP JP2017027686A patent/JP2017088620A/ja active Pending
- 2017-05-22 US US15/601,150 patent/US20180098984A1/en not_active Abandoned
- 2017-12-03 IL IL256054A patent/IL256054A/en unknown
2018
- 2018-06-04 JP JP2018106910A patent/JP2018150368A/ja active Pending
- 2018-07-26 US US16/045,792 patent/US20190201391A1/en not_active Abandoned
2019
- 2019-06-16 IL IL267381A patent/IL267381A/en unknown
- 2019-10-03 US US16/591,879 patent/US20200276185A1/en not_active Abandoned
- 2019-10-21 JP JP2019191618A patent/JP2020063248A/ja active Pending
2021
- 2021-03-12 JP JP2021039908A patent/JP2021098743A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
TWI326214B (en)	2010-06-21
TW200403997A (en)	2004-03-16
AU2003251971A1 (en)	2004-02-02
JP6097859B2 (ja)	2017-03-15
KR101622446B1 (ko)	2016-05-18
NO2013017I2 (no)	2015-09-07
FR13C0062I1 (da)	2014-01-03
HK1123741A1 (en)	2009-06-26
EP1539166B1 (en)	2008-07-02
KR20130043217A (ko)	2013-04-29
ES2309351T3 (es)	2008-12-16
CA2492081A1 (en)	2004-01-22
IL256054A (en)	2018-01-31
US20090082384A1 (en)	2009-03-26
US20190201391A1 (en)	2019-07-04
IL267381A (en)	2019-08-29
NO2013017I1 (no)	2014-06-02
JP2021098743A (ja)	2021-07-01
US20050203125A1 (en)	2005-09-15
BE2013C064I2 (da)	2022-08-09
EP3281630A1 (en)	2018-02-14
US20130072517A1 (en)	2013-03-21
AU2008201775B2 (en)	2010-05-20
CY2013041I2 (el)	2015-12-09
PL374026A1 (en)	2005-09-19
EP3824889A1 (en)	2021-05-26
EP3459547A1 (en)	2019-03-27
CY1110405T1 (el)	2012-05-23
JP2020063248A (ja)	2020-04-23
EP1539166A1 (en)	2005-06-15
FR13C0062I2 (fr)	2015-11-20
AU2008201775A1 (en)	2008-05-15
US7659282B2 (en)	2010-02-09
DK1980252T3 (da)	2015-11-30
JP2017036337A (ja)	2017-02-16
JP2016106150A (ja)	2016-06-16
US20100137352A1 (en)	2010-06-03
JP2005537268A (ja)	2005-12-08
KR20050043893A (ko)	2005-05-11
US20140045880A1 (en)	2014-02-13
PT1539166E (pt)	2008-10-14
US20180098984A1 (en)	2018-04-12
IL225191A0 (en)	2013-06-27
JP6332651B2 (ja)	2018-05-30
US20160287576A1 (en)	2016-10-06
PT1980252E (pt)	2015-12-01
KR20190143466A (ko)	2019-12-30
EP1980252A3 (en)	2008-12-24
PL398445A1 (pl)	2012-06-04
US20140288114A1 (en)	2014-09-25
HUS1300069I1 (hu)	2016-10-28
KR20120089706A (ko)	2012-08-13
NO330626B1 (no)	2011-05-30
JP5082032B2 (ja)	2012-11-28
SI1980252T1 (sl)	2016-01-29
KR20160055963A (ko)	2016-05-18
HUE028100T2 (en)	2016-11-28
PL213552B1 (pl)	2013-03-29
KR20110010669A (ko)	2011-02-01
RU2341265C2 (ru)	2008-12-20
EP2322179A1 (en)	2011-05-18
DE60321929D1 (de)	2008-08-14
IL225190A (en)	2017-03-30
US20120165363A1 (en)	2012-06-28
JP2012116858A (ja)	2012-06-21
IL225191A (en)	2017-03-30
JP2011225601A (ja)	2011-11-10
RU2005104418A (ru)	2005-10-27
LU92323I2 (fr)	2015-09-22
CY2013041I1 (el)	2015-12-09
US20150209347A1 (en)	2015-07-30
US20200276185A1 (en)	2020-09-03
US8227484B2 (en)	2012-07-24
ES2553654T3 (es)	2015-12-10
AU2010212348A1 (en)	2010-09-09
WO2004006930A1 (en)	2004-01-22
JP2018150368A (ja)	2018-09-27
IL225192A (en)	2017-12-31
IL166166A0 (en)	2006-01-15
IL211593A0 (en)	2011-05-31
JP2014058575A (ja)	2014-04-03
KR20130041296A (ko)	2013-04-24
JP2016011304A (ja)	2016-01-21
ATE399553T1 (de)	2008-07-15
HK1076052A1 (en)	2006-01-06
SI1539166T1 (sl)	2008-12-31
AU2003251971B2 (en)	2008-02-21
JP2014129384A (ja)	2014-07-10
AU2003251971B9 (en)	2008-04-24
KR101588095B1 (ko)	2016-01-25
AU2010212348B2 (en)	2013-05-09
EP1980252A2 (en)	2008-10-15
CA2492081C (en)	2010-09-07
NO20050807L (no)	2005-02-15
EP1980252B1 (en)	2015-08-19
JP2017088620A (ja)	2017-05-25
JP6074000B2 (ja)	2017-02-01

Publication	Publication Date	Title
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
LTPA2017009I1 (lt)	2017-04-25	Brutono tirozinkinazės inhibitoriai
ATE556713T1 (de)	2012-05-15	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
JO2373B1 (en)	2006-12-12	W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE512163T1 (de)	2011-06-15	Verabreichung von mitteln zur behandlung von entzündungen
CY1107467T1 (el)	2012-12-19	Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
ATE350377T1 (de)	2007-01-15	Substituierte 3-pyrrolidin-indol-derivate
DK1545537T3 (da)	2007-07-02	Alfa-7-nikotinreceptoragonister og statiner i kombination
MY135829A (en)	2008-07-31	Analeptic and drug combinations
ATE554753T1 (de)	2012-05-15	2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
NO20055563L (no)	2005-11-24	Midler for behandlingen av lavere abdominale lidelser
DK0862454T3 (da)	2002-12-30	CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DK1708693T3 (da)	2009-06-29	Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
CY1117102T1 (el)	2017-04-05	Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
BG105763A (en)	2002-03-29	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors